• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CHM
Click for more information
0.00% 2.9¢

CHIMERIC THERAPEUTICS LIMITED - News & Media

Market Cap $24.70M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company.... Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company. The Company is focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its pipeline includes CHM 1101 and CHM 2101. Its CHM 1101 (CLTX CAR-T) is a CAR-T therapy developed for the treatment of patients with solid tumors. CHM-1101 is being studied in a Phase I clinical trial in recurrent/ progressive glioblastoma. CHM 2101 is a third generation CDH17 CAR T, which is in preclinical development with a planned Phase I clinical trial in neuroendocrine tumors, colorectal, pancreatic and gastric cancer. Its pipeline also includes the CORE-NK platform, a clinically validated, off-the-shelf natural killer (NK) cell therapy platform to their portfolio (CHM 0201). The Company is also focused on the development of four NK and CAR NK assets with plans for Phase I clinical trials in solid tumors and blood cancers.More

Articles & Videos

Chimeric Therapeutics treats first patient in Advent-AML phase 1B clinical trial

Chimeric Therapeutics (ASX:CHM) has treated the first patient in its Advent-AML phase 1B clinical trial at The University of Texas MD Anderson Cancer Center.

08 Feb 2024 13:19 (AEDT)

Chimeric Therapeutics announces positive preclinical data for CHM 1301

Chimeric Therapeutics (ASX:CHM) has announced positive in vitro data for CHM 1301, the company's next-generation CLTX CAR NK cell therapy program.

23 Nov 2023 12:53 (AEDT)

Chimeric Therapeutics to raise $10m through entitlement offer

Chimeric Therapeutics (ASX:CHM) has announced it will conduct an equity raising through a two-for-three entitlement offer of new shares, with the goal of raising up to $10 million.

25 Oct 2023 13:11 (AEDT)

Chimeric Therapeutics (ASX:CHM) completes dose escalation in phase 1A brain cancer trial

Chimeric Therapeutics (ASX:CHM) has treated the third patient participating in its phase 1A dose escalation study at the City of Hope Hospital in California.

29 Aug 2023 14:54 (AEST)



(20min delay)
Last
2.9¢ 		Change
0.000(0.00%) 		Mkt cap ! $24.70M
Open High Low Value Volume
2.9¢ 2.9¢ 2.8¢ $25.82K 913.8K

Buyers (Bids)

No. Vol. Price($)
6 5503899 2.7¢
 

Sellers (Offers)

Price($) Vol. No.
3.0¢ 301388 4
View Market Depth
Last trade - 16.10pm 03/05/2024 (20 minute delay) ?
Last
2.9¢ 		  Change
0.000 ( 3.57 %)
Open High Low Volume
2.8¢ 2.9¢ 2.7¢ 743366
Last updated 15.44pm 03/05/2024 ?
CHM (ASX) Chart

Top Stories

Car EV-olution accelerates Oz into pole position

As the world steers towards a more sustainable future, the surge in electric vehicle (EV) sales is turning industries upside down, and mining is no exception. Australia, famous for its treasure trove of minerals, finds itself right in the middle of this shift, which raises two questions. Firstly,...
Why Princeton Professor rates BlinkLab's autism & ADHD screening app In this interview with Sonia Madigan, Professor Sam Wang of Princeton University discusses the development and potential of BlinkLab's (ASX:BB1) AI-driven smartphone app, designed to screen for autism and ADHD.
Dancing to that same 70s tune, China, and why I'm backing gold It is too early to judge what concrete measures the Future Made in Australia policy will entail. However, any policy which has a stated aim to screen qualifying capital for suitability at a government level, does not seem like a strong signal for foreigners to get on a plane, come visit some mine sites and invest.
Provident Aurum's off-market bid sends Sihayo shares soaring Small-cap mineral and gold explorer, Sihayo Gold (ASX:SIH) shares have soared, on news that the company has received intentions from Provident Aurum Pte to make an off-market takeover offer to acquire all shares of Sihayo Gold.
Macquarie profits fall 32% on 'market volatility' and low-achieving 'green investments' Macquarie Bank has shaved more than 30 percent off its net profit in the final quarter of the 2024 financial year (FY 2024), compared to the same time last year, with executives speaking cautiously about market volatility and @lower asset realisations’ from green investments, but ...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.